HCW Biologics $10.2M Debt Financing with Streeterville Capital, LLC
HCW Biologics entered into a Notes Purchase Agreement for the issuance of two secured promissory notes totaling $10.2 million in principal ($3.2M A-1 Note and $7.0M B Note). The financing provides immediate net proceeds of approximately $3.0 million, with the remaining $7.0 million held in a restricted account to be released as the A-1 Note is repaid. Proceeds will fund the Phase 1 clinical study of HCW9302 for alopecia areata through its expected readout in Q1 2027.
- Value
- $10.2M
- Counterparty
- Streeterville Capital, LLC
- Term
- 24 months